TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05305950

Intervention type: OTHER
Intervention: Patient population
Description: Questionnaire, standard of care

Intervention type: OTHER
Intervention: Patient population
Description: Questionnaire, standard of care
Study: NCT04784637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web Simulation Tool (WST)
Description: WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Web Simulation Tool (WST)
Description: WST will allow users of the Control-IQ system replay treatment scenarios in computer simulation, thereby allowing user training with carbohydrate and insulin action.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioral Adaptation Module (BAM)
Description: BAM provides on-demand information to the participant primarily on glycemic risks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Titration Module (ATM)
Description: ATM provides recommendations to the participant to periodically update insulin parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Titration Module (ATM)
Description: ATM provides recommendations to the participant to periodically update insulin parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID) System
Description: The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID) System
Description: The t:slim X2 insulin pump with Control-IQ technology, Tandem Diabetes Care will be the AID in this study.
Study: NCT05157048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal-filtered cigarette
Description: Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Charcoal-filtered cigarette
Description: Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-charcoal filtered cigarette
Description: Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-charcoal filtered cigarette
Description: Participants will smoke two visually identical cigarettes, one with a charcoal filter and one with a non-charcoal filter, in counterbalanced order. The charcoal filter cigarette will be a Natural American Spirit Sky cigarette; the non-charcoal filter cigarette will be a Natural American Spirit Orange cigarette.
Study: NCT06137781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six weeks of digital prehabilitation
Description: All participants will be allocated to receive six weeks of digital prehabilitation via PreActiv's website, plus usual care.
Study: NCT02615184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole capsules
Study: NCT05133908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dCBTi-ADHD
Description: The dCBTi adopts a multi-module approach, consisting of 7 weekly modules including psychoeducation on sleep and ADHD, insomnia, organization strategies and distractibility reduction skills, sleep hygiene, sleep restriction and prescription, circadian-related activity scheduling, stimulus control, relaxation and worry time, cognitive restructuring, and relapse prevention. In each module, participants will watch short videos to learn strategies to improve their sleep. A virtual coach is also included in the app functionality. It will be in the form of a text-based forced-choice conversation bot. It will initiate conversations with the users to check their understanding of treatment materials and guide them to come up with specific action plans to implement the treatment strategies.
Study: NCT06127225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proliverenol
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proliverenol
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily
Study: NCT04785352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition Intervention
Description: One egg per day for six months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grandi Byen
Description: Multicomponent intervention on responsive parenting, nutrition, hygiene + one egg per day for 6 months
Study: NCT06281769

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D multi-parametric ultrasound targeted biopsy pathway using PcaVision
Description: The procedure of 3D multiparametric ultrasound consists of 3 components: (1) intravenous administration of ultrasound contrast; (2) rectal multi-parametric ultrasound imaging; (3) PCaVision: artificial intelligence algorithm analyzing the images.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI targeted biopsy pathway
Description: MRI sequences will include at least T1-weighted, T2-weighted, Diffusion-weighted imaging (DWI) and calculation of apparent diffusion coefficient (ADC) maps. Scoring of suspicion will be performed using the European Society of Urogenital Radiology (ESUR) PI-RADS standardized scoring system. All lesions will be marked and delineated for MRI-TRUS fusion 3D multiparametric ultrasound (mpUS).
Study: NCT06439784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body SPECT/CT
Description: Patient will unergo a whole body SPECT/CT in treatment position
Study: NCT04802590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: 560mg/d continuously from C1D2 to end C24
Study: NCT05619822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + A comprehensive third-generation intervention
Description: This is a individual intervention with with a total of 12 sessions: Session 1. Constructing the Therapy Experience. Session 2. Life history and immediate reactions to trauma. Session 3. Preparing to deal with trauma. Session 4. Regulating emotions. Session 5-9. Focusing on retelling and processing the traumatic event (EMDR PHASES_PHASE 3: Evaluation of the traumatic memory. EMDR PHASE 4: Desensitization. EMDR PHASE 5: Positive Belief Installation. PHASE 6: Body Scan). Session 9. Re-evaluating traumatic memory and self-care through positive emotions. Session 10. Cultivating self-kindness. Session 11. Developing a healthy identity. Session 12. Building a better future

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: Treatment as usual
Study: NCT04802590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: 560mg/d continuously from C1D2 to end C24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 10 MG Oral Tablet [Venclexta]
Description: 20mg/d from C2D1 to C2D7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 50 MG Oral Tablet [Venclexta]
Description: 50mg/d from C2D8 to C2D14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax 100 MG Oral Tablet [Venclexta]
Description: 100mg/d from C2D15 to C2D21 200mg/d from C2D22 to C2D28 400mg/d from C3D1 to end C24
Study: NCT06127225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proliverenol
Description: 1 caplet of Proliverenol 500 mg twice daily 2 caplets of Proliverenol 500 mg once daily 2 caplets of Proliverenol 500 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo caplets of Proliverenol
Description: 2 caplets of Proliverenol Placebo daily
Study: NCT05886816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoquinone/mitoquinol mesylate
Description: Mitochondrial antioxidant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills
Study: NCT06002126

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert HPV
Description: The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV16, HPV18/45, HPV 31/33/35/52/58, HPV51/59, HPV39/68/56/66 all with a corresponding cycle threshold.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: S5 DNA methylation classifier
Description: The S5 classifier is a combination of DNA methylation levels of the late regions of the L1 and L2 proteins from HPV16, HPV18, HPV31, and HPV33, as well as DNA methylation of the promotor region of the human tumor suppressor gene, Erythrocyte Membrane Protein Band 4.1 Like 3 (EPB41L3).
Study: NCT04923815

Intervention type: DEVICE
Intervention: THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter
Description: THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.

Intervention type: DEVICE
Intervention: THERMOCOOL SMARTTOUCH® Diagnostic/Ablation Deflectable Tip Catheter
Description: THERMOCOOL SMARTTOUCH® catheter is a pressure catheter irrigated with cold saline, contact force sensing catheter. When used with Carto ®3 system, this catheter can provide a real time measurement for contact force. The magnitude and direction of the contact force can be displayed visually in the form of vector arrow on the top of catheter in Carto®3 system. It can be used for electrophysiological mapping and ablation of the heart.
Study: NCT05686486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi inspired gymnastics
Description: The intervention programme will address the themes of relax and seek flexibility and contact and follow. The programme will be divided into four parts with six sessions per part. A typical session will be as follows:~* Joint warm-up~* A body session focused on relaxation and flexibility in different planes: sagittal/sagittal and frontal/sagittal, frontal and transversal/sagittal, frontal and transversal.~* A more playful session in pairs on the theme of contact and follow. Example: put the back of your hand against the back of your partner's hand and initiate movements and the other must follow without resistance.
Study: NCT06342609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg per day of Colchicine orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: 0.5mg per day of Colchicine orally administered
Study: NCT05440565

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fecal immunochemical test
Description: Fecal immunochemical test can concentrate the high-risk population.
Study: NCT04709471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will reduce their nicotine intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Participants will reduce their nicotine intake

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juul e-cigarette
Description: Participants will switch to Juul pods containing less nicotine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduction
Description: Participants will reduce the number of Juul pods that they use
Study: NCT05943977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 DMID
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 DMID
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 DMID
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 DMID
Description: 130 mg of the MB-102 Domestic Manufactured Investigational Drug administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 OMID
Description: 130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102 OMID
Description: 130 mg of the MB-102 Overseas Manufactured Investigational Drug (OMID) administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered over 30-60 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR sensor placed on their chests, and the MediBeacon Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements terminated by the system when a low signal-to-noise threshold is reached.
Study: NCT05440565

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: APCS score
Description: APCS score can concentrate the high-risk population.
Study: NCT05604586

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 100 women and men supplementing 1200 mg of N-acetylcysteine daily in three equal doses. Supplementation will last for 7 days.
Study: NCT04753853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction injection
Description: intra- and peri-tendon ultrasound-guided injection of Stromal Vascular Fraction
Study: NCT05700136

Intervention type: BEHAVIORAL
Intervention: MOMENT
Description: Prenatal and postnatal factors including maternal, environment, and infant circadian rhythm were studied to determine its effect on infant growth and temperament.
Study: NCT06468202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Participants will be assigned to 81mg Aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 162 mg
Description: Participants will be assigned to 162mg Aspirin
Study: NCT05970614

Intervention type: OTHER
Group type: OTHER
Intervention: Eye masks and ear plugs
Description: Eye masks and ear plugs will be applied to patients for 3 days between 22:00 and 06:00.
Study: NCT06237348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Description: Daily airway clearance therapy at home during 2 months

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Daily airway clearance therapy at home during 2 months

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Control
Description: Daily airway clearance therapy at home during 2 months
Study: NCT04738838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Intranasal treatment with oxytocin via nasal spray (48 IU per dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Intranasal treatment with placebo via nasal spray
Study: NCT04556084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab will be given as a 28-day continuous infusion with 14-days in between Cycle 1 and Cycle 2 as per the package insert and FDA approved labeling.~Patient weight greater than or equal to 45kg will receive 28 mcg/day~Patient weight less than 45kg will receive 15 mcg/m2/day
Study: NCT06300398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-to-match IAMA-6 liquid suspension
Study: NCT05218603

Intervention type: DRUG
Intervention: Bortezomib
Description: Maintenance: Administration as per routine clinical practice.

Intervention type: DRUG
Intervention: Daratumumab
Description: Maintenance: Administration as per routine clinical practice.
Study: NCT03998592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (50 µg)
Description: Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (100 µg)
Description: Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pyogenes vaccine (200 µg)
Description: Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo without active component
Study: NCT06503003

Intervention type: DEVICE
Intervention: Leonardo® Diode laser
Description: The intervention involves non-ablative dual-wavelength diode laser therapy for treating Genitourinary Syndrome of Menopause (GSM). This includes three monthly sessions of the Leonardo® Diode laser (Biolitec®), with wavelengths of 980 nm and 1470 nm, delivering 8 pulses per centimeter along the vaginal canal, using local lidocaine gel as an anesthetic. Evaluations are conducted at baseline, 3 months, and 6 months post-treatment.
Study: NCT05450991

Intervention type: PROCEDURE
Intervention: Pull through
Description: Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included

Intervention type: PROCEDURE
Intervention: Pull through
Description: Children diagnosed with Hirschpsrung's Disease or an anorectal malformation, with or without operative intervention will be included
Study: NCT06371417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAY121
Description: Injection
Study: NCT06472089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMT-CARE
Description: Therapist-delivered psychosocial intervention comprised of 6 sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Meeting a transplant social worker prior to HCT and as needed for extra visits
Study: NCT05080192

Intervention type: DRUG
Intervention: Fenofibrate
Description: 145 mg/d of Tricor (administered as part of the parent FERMIN trial) for 10 days, or renal corrected dose equivalent (depending on renal function)

Intervention type: DRUG
Intervention: Placebo
Description: Matching placebo (once/day) for 10 days
Study: NCT06303986

Intervention type: DEVICE
Group type: OTHER
Intervention: Neomonki
Description: The Neomonki is a monitoring kit for hospital use in neonates with Neonatal Abstinence Syndrome (NAS).